Hermo Pharma Attracted CNS Market Leaders at Bio-Europe 2010
Hermo Pharma Ltd. today announced that its partnering position was significantly improved at Bio-Europe 2010. Hermo Pharma will use the contacts created at the partnering event for implementation of the research and development programs as well as for delivering the products eventually to the market. Hermo Pharma is developing partnerships for all of the pipeline products in the company’s portfolio.
The R&D pipeline of the Hermo Pharma consists following projects: Treatment of Amblyopia in adults (entering Phase IIa) and disease-modifying treatment for Parkinson’s disease with CDNF molecule. In addition, Hermo Pharma has unique and proof-of-concept proven strategies to modulate RAGE and TrkB receptor-mediated CNS biology, both projects at discovery phase.
“There seems to be even stronger shift in the pharmaceutical industry towards earlier partnerships than we had originally anticipated. Also, the level of interest towards our product portfolio puts our company into a promising position. I’m especially glad that almost all CNS market leading companies indicated interest towards our portfolio during the Bio-Europe 2010. We plan to have a non-confidential, science-based webinar regarding our R&D portfolio during Spring 2011 to satisfy the information needs of our potential partner candidates and by that arrangement effectively drive the start of the preliminary business discussions with selected companies”, commented Mr. Lahdenperä.